|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GCAT |
Gene summary for GCAT |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GCAT | Gene ID | 23464 |
| Gene name | glycine C-acetyltransferase | |
| Gene Alias | KBL | |
| Cytomap | 22q13.1 | |
| Gene Type | protein-coding | GO ID | GO:0006082 | UniProtAcc | O75600 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23464 | GCAT | LZE7T | Human | Esophagus | ESCC | 5.31e-07 | 4.59e-01 | 0.0667 |
| 23464 | GCAT | LZE24T | Human | Esophagus | ESCC | 6.90e-17 | 3.97e-01 | 0.0596 |
| 23464 | GCAT | LZE21T | Human | Esophagus | ESCC | 3.00e-03 | 3.04e-01 | 0.0655 |
| 23464 | GCAT | P1T-E | Human | Esophagus | ESCC | 4.51e-06 | 3.81e-01 | 0.0875 |
| 23464 | GCAT | P2T-E | Human | Esophagus | ESCC | 4.12e-11 | 2.07e-01 | 0.1177 |
| 23464 | GCAT | P4T-E | Human | Esophagus | ESCC | 1.33e-22 | 4.90e-01 | 0.1323 |
| 23464 | GCAT | P5T-E | Human | Esophagus | ESCC | 1.58e-04 | 1.28e-01 | 0.1327 |
| 23464 | GCAT | P8T-E | Human | Esophagus | ESCC | 2.43e-08 | 1.87e-01 | 0.0889 |
| 23464 | GCAT | P9T-E | Human | Esophagus | ESCC | 5.13e-15 | 3.61e-01 | 0.1131 |
| 23464 | GCAT | P10T-E | Human | Esophagus | ESCC | 5.63e-60 | 1.05e+00 | 0.116 |
| 23464 | GCAT | P11T-E | Human | Esophagus | ESCC | 7.86e-15 | 5.67e-01 | 0.1426 |
| 23464 | GCAT | P12T-E | Human | Esophagus | ESCC | 4.93e-10 | 2.17e-01 | 0.1122 |
| 23464 | GCAT | P15T-E | Human | Esophagus | ESCC | 1.57e-14 | 3.23e-01 | 0.1149 |
| 23464 | GCAT | P16T-E | Human | Esophagus | ESCC | 1.92e-58 | 1.09e+00 | 0.1153 |
| 23464 | GCAT | P17T-E | Human | Esophagus | ESCC | 1.24e-15 | 6.16e-01 | 0.1278 |
| 23464 | GCAT | P20T-E | Human | Esophagus | ESCC | 1.17e-06 | 1.84e-01 | 0.1124 |
| 23464 | GCAT | P21T-E | Human | Esophagus | ESCC | 9.73e-65 | 1.32e+00 | 0.1617 |
| 23464 | GCAT | P22T-E | Human | Esophagus | ESCC | 5.85e-19 | 3.89e-01 | 0.1236 |
| 23464 | GCAT | P23T-E | Human | Esophagus | ESCC | 9.57e-18 | 4.91e-01 | 0.108 |
| 23464 | GCAT | P24T-E | Human | Esophagus | ESCC | 8.67e-17 | 3.99e-01 | 0.1287 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00442827 | Esophagus | ESCC | small molecule catabolic process | 201/8552 | 376/18723 | 1.35e-03 | 6.41e-03 | 201 |
| GO:004428221 | Liver | HCC | small molecule catabolic process | 225/7958 | 376/18723 | 6.50e-12 | 2.80e-10 | 225 |
| GO:001605421 | Liver | HCC | organic acid catabolic process | 152/7958 | 240/18723 | 5.11e-11 | 1.92e-09 | 152 |
| GO:00463952 | Liver | HCC | carboxylic acid catabolic process | 149/7958 | 236/18723 | 1.11e-10 | 3.87e-09 | 149 |
| GO:19016052 | Liver | HCC | alpha-amino acid metabolic process | 124/7958 | 195/18723 | 2.07e-09 | 5.79e-08 | 124 |
| GO:00065202 | Liver | HCC | cellular amino acid metabolic process | 167/7958 | 284/18723 | 1.91e-08 | 4.56e-07 | 167 |
| GO:00090632 | Liver | HCC | cellular amino acid catabolic process | 70/7958 | 110/18723 | 6.12e-06 | 7.52e-05 | 70 |
| GO:00090692 | Liver | HCC | serine family amino acid metabolic process | 29/7958 | 40/18723 | 1.17e-04 | 9.87e-04 | 29 |
| GO:00090662 | Liver | HCC | aspartate family amino acid metabolic process | 34/7958 | 49/18723 | 1.28e-04 | 1.06e-03 | 34 |
| GO:19016062 | Liver | HCC | alpha-amino acid catabolic process | 53/7958 | 87/18723 | 4.01e-04 | 2.71e-03 | 53 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa002602 | Liver | HCC | Glycine, serine and threonine metabolism | 28/4020 | 40/8465 | 3.28e-03 | 1.07e-02 | 5.93e-03 | 28 |
| hsa002603 | Liver | HCC | Glycine, serine and threonine metabolism | 28/4020 | 40/8465 | 3.28e-03 | 1.07e-02 | 5.93e-03 | 28 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| GCAT | SNV | Missense_Mutation | c.325G>A | p.Glu109Lys | p.E109K | O75600 | protein_coding | tolerated(0.16) | benign(0.021) | TCGA-A8-A09G-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| GCAT | SNV | Missense_Mutation | rs201266387 | c.607C>T | p.Arg203Cys | p.R203C | O75600 | protein_coding | deleterious(0.02) | benign(0.013) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| GCAT | SNV | Missense_Mutation | c.332N>C | p.Ile111Thr | p.I111T | O75600 | protein_coding | deleterious(0.02) | possibly_damaging(0.612) | TCGA-C8-A26X-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | |
| GCAT | SNV | Missense_Mutation | novel | c.308N>A | p.Gly103Asp | p.G103D | O75600 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| GCAT | SNV | Missense_Mutation | novel | c.65N>T | p.Ser22Leu | p.S22L | O75600 | protein_coding | deleterious_low_confidence(0.01) | benign(0.169) | TCGA-EX-A69L-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| GCAT | SNV | Missense_Mutation | novel | c.155N>T | p.Ser52Phe | p.S52F | O75600 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| GCAT | SNV | Missense_Mutation | rs750055272 | c.1070N>A | p.Arg357His | p.R357H | O75600 | protein_coding | deleterious(0.03) | probably_damaging(0.995) | TCGA-VS-A9V1-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| GCAT | SNV | Missense_Mutation | rs200392738 | c.809N>A | p.Arg270Gln | p.R270Q | O75600 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| GCAT | SNV | Missense_Mutation | rs139816860 | c.1216N>A | p.Val406Met | p.V406M | O75600 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| GCAT | SNV | Missense_Mutation | novel | c.493G>A | p.Ala165Thr | p.A165T | O75600 | protein_coding | tolerated(0.14) | benign(0.176) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |